November 1 2019, David R Brown
IMCD to acquire Swiss-based active pharmaceutical ingredients distributor, DCS Pharma AG
IMCD N.V. ("IMCD"), a leading distributor of specialty chemicals and food ingredients, has signed an agreement to acquire in two steps, 100% of the outstanding shares of Swiss based pharmaceutical distributor DCS Pharma AG : 90% of the shares upon fulfilment of transaction-related conditions and the remaining 10% as per 31 December 2021.
I am absolutely excited about the potential of coupling DCS Pharma's leading position in active pharmaceutical ingredients with IMCD's geographic coverageBeat Berger
CEO DCS Pharma AG
DCS Pharma AG headquartered in Basel, was founded in 2016 by the two Swiss pharmaceutical distributors Dolder AG and ChemSwiss AG and operates in eight markets such as Spain, Italy, Germany, Mexico, and China. In 2018, the company generated a revenue of CHF 68 million with 64 employees. DCS' product portfolio covers a range of Active Pharmaceutical Ingredients for the pharmaceutical and nutraceutical industries.
John Robinson, IMCD Business Group Director Pharmaceuticals comments, &ldquoDCS is a significant acquisition for the development of our Pharmaceutical business, not only in expanding our global footprint, but moreover in exploiting the clear pipeline, formulation and marketing synergies between active pharmaceutical Ingredients and excipients.”
Beat Berger, CEO DCS Pharma AG adds, &ldquoI am absolutely excited about the potential of coupling DCS Pharma's leading position in active pharmaceutical ingredients with IMCD's geographic coverage, laboratory network and excellence in excipients. Our existing and future partners will be able to benefit from a significantly increased network within the pharmaceutical industry.”
About IMCD N.V.
IMCD is a market-leader in the sales, marketing and distribution of speciality chemicals and food ingredients. Its result driven professionals provide market-focused solutions to suppliers and customers across EMEA, Asia-Pacific and Americas, offering a range of comprehensive product portfolios, including innovative formulations that embrace industry trends. Listed at Euronext, Amsterdam (IMCD), IMCD realised revenues of EUR 2,379 million in 2018 with more than 2,800 employees in over 45 countries on 6 continents. IMCD's dedicated team of technical and commercial experts work in close partnership to tailor best in class solutions and provide value through expertise for around 37,000 customers and a diverse range of world class suppliers
Source(s): IMCD Press Release